Edition:
United States

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

25.45EUR
23 May 2018
Change (% chg)

€0.20 (+0.79%)
Prev Close
€25.25
Open
€25.20
Day's High
€25.45
Day's Low
€25.05
Volume
8,446
Avg. Vol
32,692
52-wk High
€27.70
52-wk Low
€17.90

Chart for

About

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactur... (more)
No analyst recommendations are available for .

Overall

Beta: 0.62
Market Cap(Mil.): €999.67
Shares Outstanding(Mil.): 39.57
Dividend: 0.05
Yield (%): 0.18

Financials

  BIOG_p.DE Industry Sector
P/E (TTM): 58.98 30.95 32.75
EPS (TTM): 0.47 -- --
ROI: 1.01 14.84 14.38
ROE: 2.12 16.34 16.07

BRIEF-Biotest FY Revenue Falls To EUR 378.1 Mln On Recall Of Human Albumin

* DGAP-ADHOC: BIOTEST AG: BIOTEST REACHES FY 2017 EBIT GUIDANCE

Feb 27 2018

BRIEF-Biotest says Tiancheng to enter into domination agreement

* DGAP-ADHOC: BIOTEST AG: TIANCHENG INTENDS TO ENTER INTO A DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT WITH BIOTEST AG

Feb 08 2018

BRIEF-Biotest: Creat Takeover Of Biotest Closed

* MAJORITY SHAREHOLDING (APPROX. 90% OF BIOTEST'S ORDINARY SHARES AND VOTING SHARE CAPITAL) OF CREAT IN BIOTEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 31 2018

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

FRANKFURT Biotest said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.

Jan 19 2018

BRIEF-Biotest: All Conditions Met For Creat Takeover Of Biotest

* DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST

Jan 19 2018

BRIEF-Biotest: Trimodulin Concept For Phase III Study Coordinated With The Authorities

* DGAP-NEWS: BIOTEST AG: TRIMODULIN: CONCEPT FOR PHASE III STUDY SUCCESSFULLY COORDINATED WITH THE AUTHORITIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 20 2017

Earnings vs. Estimates